Contact: Mary Leach, (617) 573-4170
Predicting the Next Eye Pathogen; Analysis of a Novel Adenovirus
Research Outlined in mBio
BOSTON (April 10, 2013) – The ongoing dance between a virus and its host distinctly shapes how the virus evolves. While human adenoviruses typically cause mild infections, recent reports have described newly characterized adenoviruses that can cause severe, sometime fatal, human infections.
Researchers from the Massachusetts Eye and Ear and Harvard Medical School, Provincial Laboratory for Public Health, School of Systems Biology, George Mason University, and the Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center report a systems biology approach to show how evolution has affected the disease potential of a recently identified novel human adenovirus. Their approach is based on the belief that understanding viral evolution and pathogenicity is essential to our capacity to foretell the potential impact on human disease for new and emerging viruses. Their study is now published in mBio.
Since the first adenovirus was characterized in 1953, 69 human adenoviruses (HAdVs) have been recognized as unique types. Analysis of whole-genome sequence data for existing and new HAdVs confirmed a critical role for homologous recombination in adenovirus evolution, leading to new and sometime serious human infections. The emergence of new HAdV types, with several associated with severe eye infection, promoted the investigators to apply a systems biology approach to try to predict the ocular tropism of a previously uncharacterized and highly novel HAdV, isolated by nasopharyngeal swab from a 4-month-old boy with several bronchiolitis.
A combined genomic, bioinformatics and biological analysis identified a unique deletion in a key protein of the viral capsid and further suggested the potential of the virus to cause severe ocular infection. The results point toward a possible approach for predicting pathogenicity for newly identified and recently emergent human pathogens.
The study was supported NIH grants EY013124, EY021558 and EY014104, a Research to Prevent Blindness Senior Scientific Investigator Award, the Falk Foundation and the Massachusetts Lions Eye Research Fund.
About Massachusetts Eye and Ear
Mass. Eye and Ear clinicians and scientists are driven by a mission to find cures for blindness, deafness and diseases of the head and neck. After uniting with Schepens Eye Research Institute Mass. Eye and Ear in Boston became the world's largest vision and hearing research center, offering hope and healing to patients everywhere through discovery and innovation. Mass. Eye and Ear is a Harvard Medical School teaching hospital and trains future medical leaders in ophthalmology and otolaryngology, through residency as well as clinical and research fellowships. Internationally acclaimed since its founding in 1824, Mass. Eye and Ear employs full-time, board-certified physicians who offer high-quality and affordable specialty care that ranges from the routine to the very complex. U.S. News & World Report’s “Best Hospitals Survey” has consistently ranked the Mass. Eye and Ear Departments of Otolaryngology and Ophthalmology as top five in the nation.